Suppression of Rev3, the catalytic subunit of Polζ, sensitizes drug-resistant lung tumors to chemotherapy
Open accessAbstract
Platinum-based chemotherapeutic drugs are front-line therapies for the treatment of non-small cell lung cancer. However, intrinsic drug resistance limits the clinical efficacy of these agents. Recent evidence suggests that loss of the translesion polymerase, Polζ, can sensitize tumor cell lines to cisplatin, although the relevance of these findings to the treatment of chemoresistant tumors in vivo has remained unclear. Here, we describe a tumor transplantation approach that enables the rapid introduction of defined genetic lesions into a preclinical model of lung adenocarcinoma. Using this approach, we examined the effect of impaired translesion DNA synthesis on cisplatin response in aggressive late-stage lung cancers. In the presence of reduced levels of Rev3, an essential component of Polζ, tumors exhibited pronounced sensitivity to cisplatin, leading to a significant extension in overall survival of treated recipient mice. Additionally, treated Rev3-deficient cells exhibited reduced cisplatin-induced mutation, a process that has been implicated in the induction of secondary malignancies following chemotherapy. Taken together, our data illustrate the potential of Rev3 inhibition as an adjuvant therapy for the treatment of chemoresistant malignancies, and highlight the utility of rapid transplantation methodologies for evaluating mechanisms of chemotherapeutic resistance in preclinical settings.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Targeting the translesion synthesis polymerase REV3 restores cisplatin sensitivity to lung tumors.
“targeting the translesion synthesis polymerase REV3, which restores cisplatin sensitivity to lung tumors [82]”
From Hereditary Breast Cancer and the BRCA1-Associated FANCJ/BACH1/BRIP1 (2011) · cites this paper as [82]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · see citing works
Friedberg, E. C., Walker, G. C., Siede, W., Wood, R. D., Schultz, R. A., & Ellenberger, T. (2005) · doi:10.1128/9781555816704 · Cited by 5,683 · see citing works
Self-citationSpecific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198 · see citing works
Direct Cellular Responses to Platinum-Induced DNA Damage
Jung, Y., & Lippard, S. J. (2007) · Chemical Reviews · doi:10.1021/cr068207j · Cited by 1,393 · see citing works
The mighty mouse: genetically engineered mouse models in cancer drug development
Sharpless, N. E., & DePinho, R. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2110 · Cited by 660 · see citing works
Eukaryotic Translesion Polymerases and Their Roles and Regulation in DNA Damage Tolerance
Waters, L. S., Minesinger, B. K., Wiltrout, M. E., D'Souza, S., Woodruff, R. V., & Walker, G. C. (2009) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00034-08 · Cited by 591 · see citing works
Self-citationProbing tumor phenotypes using stable and regulated synthetic microRNA precursors
Dickins, R., Hemann, M., Zilfou, J. T., Simpson, D. R., Ibarra, I., Hannon, G., & Lowe, S. (2005) · Nature Genetics · doi:10.1038/ng1651 · Cited by 561 · see citing works
Self-citationMechanism of Replication-Coupled DNA Interstrand Crosslink Repair
Räschle, M., Knipscheer, P., Enoiu, M., Angelov, T., Sun, J., Griffith, J. D., Ellenberger, T., Schärer, O. D., & Walter, J. C. (2008) · Cell · doi:10.1016/j.cell.2008.08.030 · Cited by 507 · see citing works
Fuertes, M., Castilla, J., Alonso, C., & Pérez, J. (2003) · Current Medicinal Chemistry · doi:10.2174/0929867033368484 · Cited by 432 · see citing works
An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis.
Sweet-Cordero, A., Mukherjee, S., Subramanian, A., You, H., Roix, J. J., Ladd-Acosta, C., Mesirov, J., Golub, T. R., & Jacks, T. (2005) · Nature Genetics · doi:10.1038/ng1490 · Cited by 414 · see citing works
Self-citationCancer Modeling in the Modern Era
Dyke, T. V., & Jacks, T. (2002) · Cell · doi:10.1016/s0092-8674(02)00621-9 · Cited by 355 · see citing works
Self-citationTopoisomerase levels determine chemotherapy response in vitro and in vivo
Burgess, D. J., Doles, J. D., Zender, L., Xue, W., Ma, B., McCombie, W. R., Hannon, G. J., Lowe, S. W., & Hemann, M. T. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803513105 · Cited by 302 · see citing works
Self-citationTwo-polymerase mechanisms dictate error-free and error-prone translesion DNA synthesis in mammals
Shachar, S., Ziv, O., Avkin, S., Adar, S., Wittschieben, J., Reißner, T., Chaney, S., Friedberg, E. C., Wang, Z., Carell, T., et al. (2009) · The EMBO Journal · doi:10.1038/emboj.2008.281 · Cited by 284 · see citing works
Brozović, A., Ambriović‐Ristov, A., & Osmak, M. (2010) · Critical Reviews in Toxicology · doi:10.3109/10408441003601836 · Cited by 263 · see citing works
Goss, G. D., Arnold, A., Shepherd, F. A., Dediu, M., Ciuleanu, T., Fenton, D. W., Zukin, M., Walde, D., Laberge, F., Vincent, M. D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.9427 · Cited by 234 · see citing works
Error-prone translesion synthesis mediates acquired chemoresistance
Xie, K., Doles, J. D., Hemann, M. T., & Walker, G. C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011412107 · Cited by 222 · see citing works
Self-citationOliver, T., Mercer, K. L., Sayles, L., Burke, J., Mendus, D., Lovejoy, K. S., Cheng, M., Subramanian, A., Mu, D., Powers, S., et al. (2010) · Genes & Development · doi:10.1101/gad.1897010 · Cited by 220 · see citing works
Self-citationAhmad, S. (2010) · Chemistry & Biodiversity · doi:10.1002/cbdv.200800340 · Cited by 215 · see citing works
DNA polymerase zeta (pol ζ) in higher eukaryotes
Gan, G. N., Wittschieben, J. P., Wittschieben, B. Ø., & Wood, R. D. (2007) · Cell Research · doi:10.1038/cr.2007.117 · Cited by 202 · see citing works
Schärer, O. D. (2005) · ChemBioChem · doi:10.1002/cbic.200400287 · Cited by 191 · see citing works
Nojima, K., Hochegger, H., Saberi, A., Fukushima, T., Kikuchi, K., Yoshimura, M., Orelli, B. J., Bishop, D. K., Hirano, S., Ohzeki, M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1214 · Cited by 185 · see citing works
Bartz, S. R., Zhang, Z., Burchard, J., Imakura, M., Martin, M. M., Palmieri, A., Needham, R. H. V., Guo, J., Gordon, M. L., Chung, N., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.01229-06 · Cited by 177 · see citing works
Hicks, J. K., Chute, C. L., Paulsen, M. T., Ragland, R. L., Howlett, N. G., Guéranger, Q., Glover, T. W., & Canman, C. E. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00993-09 · Cited by 129 · see citing works
Loss of DNA Polymerase ζ Causes Chromosomal Instability in Mammalian Cells
Wittschieben, J. P., Reshmi, S. C., Gollin, S. M., & Wood, R. D. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2982 · Cited by 127 · see citing works
Meacham, C. E., Ho, E. E., Dubrovsky, E., Gertler, F. B., & Hemann, M. T. (2009) · Nature Genetics · doi:10.1038/ng.451 · Cited by 127 · see citing works
Self-citationWu, F., Lin, X., Okuda, T., & Howell, S. B. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3942 · Cited by 110 · see citing works
Li, Z., Zhang, H., McManus, T. P., McCormick, J. J., Lawrence, C. W., & Maher, V. M. (2002) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(02)00253-1 · Cited by 91 · see citing works
Lin, X., & Howell, S. B. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0491 · Cited by 83 · see citing works
Wang, H., Zhang, S., Wang, S., Lü, J., Wu, W., Weng, L., Chen, D., Zhang, Y., Lu, Z., Yang, H. J., et al. (2009) · Neuro-Oncology · doi:10.1215/15228517-2009-015 · Cited by 74 · see citing works
Schenten, D., Kracker, S., Esposito, G., Franco, S., Klein, U., Murphy, M., Alt, F. W., & Rajewsky, K. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20080669 · Cited by 70 · see citing works
Li, J., Li, Z., Du, Y., Li, X., Bao, Q., & Chen, P. (2009) · Clinical Lung Cancer · doi:10.3816/clc.2009.n.078 · Cited by 69 · see citing works
Diaz, M., Watson, N. B., Turkington, G., Verkoczy, L. K., Klinman, N. R., & McGregor, W. G. (2003) · PubMed · Cited by 67 · see citing works
Human REV1 Modulates the Cytotoxicity and Mutagenicity of Cisplatin in Human Ovarian Carcinoma Cells
Lin, X., Okuda, T., Trang, J., & Howell, S. B. (2006) · Molecular Pharmacology · doi:10.1124/mol.105.020446 · Cited by 61 · see citing works
Role of the human ERCC-1 gene in gene-specific repair of cisplatin-induced DNA damage
Larminat, F., & Bohr, V. A. (1994) · Nucleic Acids Research · doi:10.1093/nar/22.15.3005 · Cited by 60 · see citing works
Mouse Models of Human Non-Small-Cell Lung Cancer: Raising the BarPreprint
KIM, C. F. B., Jackson, E. L., Kirsch, D. G., Grimm, J., Shaw, A. T., Lane, K. M., Kissil, J. L., Olive, K. P., Sweet-Cordero, A., Weissleder, R., et al. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.037 · Cited by 58 · see citing works
Self-citationOkuda, T., Lin, X., Trang, J., & Howell, S. B. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.010579 · Cited by 53 · see citing works
Strategies for DNA interstrand crosslink repair: Insights from worms, flies, frogs, and slime molds
McVey, M. (2010) · Environmental and Molecular Mutagenesis · doi:10.1002/em.20551 · Cited by 49 · see citing works
Novel evidences for a tumor suppressor role of Rev3, the catalytic subunit of Pol ζ
Brondello, J., Pillaire, M., Rodriguez, C., Gourraud, P., Sèlves, J., Cazaux, C., & Piette, J. (2008) · Oncogene · doi:10.1038/onc.2008.212 · Cited by 39 · see citing works
Advanced Presentation of Lung Cancer in Asian Immigrants
Finlay, G. A., Joseph, B., Rodrigues, C. R., Griffith, J., & White, A. C. (2002) · CHEST Journal · doi:10.1378/chest.122.6.1938 · Cited by 33 · see citing works
Targeted Delivery of Short Interfering RNAs - Strategies for In Vivo Delivery
Wüllner, U., Neef, I., Tur, M. K., & Barth, S. (2008) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/157489209787002506 · Cited by 19 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Whole genomes redefine the mutational landscape of pancreatic cancer
Initiative, A. P. C. G., Waddell, N., Pajic, M., Patch, A.-M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., et al. (2015) · Nature · doi:10.1038/nature14169 · Cited by 2,642 · see citing works
Mechanisms of DNA damage, repair, and mutagenesis
Chatterjee, N., & Walker, G. C. (2017) · Environmental and Molecular Mutagenesis · doi:10.1002/em.22087 · Cited by 2,039 · see citing works
“Interestingly, the TLS polymerases, REV1 and REV3, were also implicated in the development of chemore- sistance in human cells and mice models, opening the possi- bility for a whole new class of promising chemotherapeutic drugs [Doles et al., 2010; Xie et al., 2010; Xu et al., 2013].”
Self-citationCancer nanomedicine: from targeted delivery to combination therapy
Xu, X., Ho, W., Zhang, X., Bertrand, N., & Farokhzad, O. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.01.001 · Cited by 693 · see citing works
Y-family DNA polymerases and their role in tolerance of cellular DNA damage
Sale, J. E., Lehmann, A. R., & Woodgate, R. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3289 · Cited by 665 · see citing works
The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance
Bouwman, P., & Jonkers, J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3342 · Cited by 615 · see citing works
Lange, S. S., Takata, K.-I., & Wood, R. D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2998 · Cited by 615 · see citing works
Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathwayPreprint
Kim, H., & D’Andrea, A. D. (2012) · Genes & Development · doi:10.1101/gad.195248.112 · Cited by 510 · see citing works
Advances in Toxicological Research of the Anticancer Drug Cisplatin
Qi, L., Luo, Q., Zhang, Y., Jia, F., Zhao, Y., & Wang, F. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00204 · Cited by 442 · see citing works
Regulation of PCNA–protein interactions for genome stability
Mailand, N., Gibbs‐Seymour, I., & Bekker‐Jensen, S. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3562 · Cited by 375 · see citing works
Xu, X., Xie, K., Zhang, X.-Q., Pridgen, E. M., Park, G. Y., Cui, D. S., Shi, J., Wu, J., Kantoff, P. W., Lippard, S. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303958110 · Cited by 340 · see citing works
Self-citationTranslesion DNA Synthesis and Mutagenesis in Eukaryotes
Sale, J. E. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012708 · Cited by 282 · see citing works
Mutational signatures are jointly shaped by DNA damage and repair
Volkova, N. V., Meier, B., González‐Huici, V., Bertolini, S., González, S., Vöhringer, H. S., Abascal, F., Martincorena, I., Campbell, P. J., Gartner, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15912-7 · Cited by 223 · see citing works
Error-prone translesion synthesis mediates acquired chemoresistance
Xie, K., Doles, J. D., Hemann, M. T., & Walker, G. C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011412107 · Cited by 222 · see citing works
Self-citationBcl-2 Antiapoptotic Family Proteins and Chemoresistance in Cancer
Maji, S., Panda, S., Samal, S. K., Shriwas, O., Rath, R., Pellecchia, M., Emdad, L., Das, S. K., Fisher, P. B., & Dash, R. (2017) · Advances in cancer research · doi:10.1016/bs.acr.2017.11.001 · Cited by 216 · see citing works
DNA damage tolerance: a double-edged sword guarding the genome.
Ghosal, G., & Chen, J. (2013) · PubMed · doi:10.3978/j.issn.2218-676x.2013.04.01 · Cited by 204 · see citing works
A Small Molecule Targeting Mutagenic Translesion Synthesis Improves Chemotherapy
Wojtaszek, J. L., Chatterjee, N., Najeeb, J., Ramos, A., Lee, M., Bian, K., Xue, J. Y., Fenton, B. A., Park, H., Li, D., et al. (2019) · Cell · doi:10.1016/j.cell.2019.05.028 · Cited by 194 · see citing works
Self-citationSrivastava, A. K., Han, C., Zhao, R., Cui, T., Dai, Y., Mao, C., Zhao, W., Zhang, X., Yu, J., & Wang, Q.-E. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1421365112 · Cited by 188 · see citing works
Lee, Y., Gregory, M., & Yang, W. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1324001111 · Cited by 167 · see citing works
Resistance to therapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4Preprint
Guillemette, S., Serra, R. W., Peng, M., Hayes, J. A., Konstantinopoulos, P. A., Green, M. R., & Cantor, S. B. (2015) · Genes & Development · doi:10.1101/gad.256214.114 · Cited by 152 · see citing works
New challenges in the use of nanomedicine in cancer therapy
Rasool, M., Malik, A., Waquar, S., Arooj, M., Zahid, S., Asif, M., Shaheen, S., Hussain, A., Ullah, H., & Gan, S. H. (2021) · Bioengineered · doi:10.1080/21655979.2021.2012907 · Cited by 135 · see citing works
Leveraging the replication stress response to optimize cancer therapy
Cybulla, E., & Vindigni, A. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00518-6 · Cited by 136 · see citing works
Response and Resistance to NF-κB Inhibitors in Mouse Models of Lung Adenocarcinoma
Xue, W., Meylan, E., Oliver, T. G., Feldser, D. M., Winslow, M. M., Bronson, R. T., & Jacks, T. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0073 · Cited by 131 · see citing works
Self-citationMulti-drug delivery nanocarriers for combination therapy
Gadde, S. (2015) · MedChemComm · doi:10.1039/c5md00365b · Cited by 127 · see citing works
Kim, B., Sun, S., Varner, J. A., Howell, S. B., Ruoslahti, E. I., & Sailor, M. J. (2019) · Advanced Materials · doi:10.1002/adma.201902952 · Cited by 122 · see citing works
Nayak, S. U., Calvo, J. A., Cong, K., Peng, M., Berthiaume, E. A., Jackson, J., Zaino, A. M., Vindigni, A., Hadden, M. K., & Cantor, S. B. (2020) · Science Advances · doi:10.1126/sciadv.aaz7808 · Cited by 117 · see citing works
DNA polymerase ζ in DNA replication and repair
Martin, S. K., & Wood, R. D. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz705 · Cited by 112 · see citing works
DNA damage repair and tolerance: a role in chemotherapeutic drug resistance
Salehan, M. R., & Morse, H. (2013) · British Journal of Biomedical Science · doi:10.1080/09674845.2013.11669927 · Cited by 112 · see citing works
Wojtaszek, J. L., Lee, C., D’Souza, S., Minesinger, B. K., Kim, H., D’Andrea, A. D., Walker, G. C., & Zhou, P. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.394841 · Cited by 111 · see citing works
Self-citationHereditary Breast Cancer and the BRCA1-Associated FANCJ/BACH1/BRIP1
Cantor, S. B., & Guillemette, S. (2011) · Future Oncology · doi:10.2217/fon.10.191 · Cited by 106 · see citing works
“Furthermore, if an unregulated FANCJ contributes to unscheduled DNA damage tolerance, targeting FANCJ could prevent chemoresistance akin to targeting the trans lesion synthesis polymerase REV3, which restores cisplatin sensitivity to lung tumors [82].”
Structural Basis of Recruitment of DNA Polymerase ζ by Interaction between REV1 and REV7 Proteins
Kikuchi, S., Hara, K., Shimizu, T., Sato, M., & Hashimoto, H. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.396838 · Cited by 103 · see citing works
Versatile in vivo regulation of tumor phenotypes by dCas9-mediated transcriptional perturbation
Braun, C. J., Bruno, P. M., Horlbeck, M. A., Gilbert, L. A., Weissman, J. S., & Hemann, M. T. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1600582113 · Cited by 101 · see citing works
Self-citationShe, R., Chakravarty, A. K., Layton, C. J., Chircus, L. M., Andreasson, J. O. L., Damaraju, N., McMahon, P. L., Buenrostro, J. D., Jarosz, D. F., & Greenleaf, W. J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1618370114 · Cited by 96 · see citing works
Mechanisms of DNA Damage Tolerance: Post-Translational Regulation of PCNA
Leung, W., Baxley, R. M., Moldovan, G., & Bielinsky, A. (2018) · Genes · doi:10.3390/genes10010010 · Cited by 96 · see citing works
Cannell, I. G., Merrick, K. A., Morandell, S., Zhu, C., Braun, C. J., Grant, R. A., Cameron, E. R., Tsao, M., Hemann, M. T., & Yaffe, M. B. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.009 · Cited by 88 · see citing works
Self-citationCompetition, collaboration and coordination – determining how cells bypass DNA damage
Sale, J. E. (2012) · Journal of Cell Science · doi:10.1242/jcs.094748 · Cited by 88 · see citing works
Can Cisplatin Therapy Be Improved? Pathways That Can Be Targeted
Ali, R., Aouida, M., Sulaiman, A. A., Madhusudan, S., & Ramotar, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137241 · Cited by 88 · see citing works
Inhibition of mutagenic translesion synthesis: A possible strategy for improving chemotherapy?
Yamanaka, K., Chatterjee, N., Hemann, M. T., & Walker, G. C. (2017) · PLOS Genetics · doi:10.1371/journal.pgen.1006842 · Cited by 87 · see citing works
Self-citationLuo, H., Chen, Z., Wang, S., Zhang, R., Qiu, W., Zhao, L., Peng, C., Xu, R., Chen, W., Wang, H., et al. (2015) · Brain · doi:10.1093/brain/awv287 · Cited by 84 · see citing works
Biomaterials in siRNA Delivery: A Comprehensive Review
Ho, W., Zhang, X., & Xu, X. (2016) · Advanced Healthcare Materials · doi:10.1002/adhm.201600418 · Cited by 83 · see citing works
DNA damage response regulation by microRNAs as a therapeutic target in cancer
Majidinia, M., & Yousefi, B. (2016) · DNA repair · doi:10.1016/j.dnarep.2016.09.003 · Cited by 82 · see citing works
Yamada, M., Watanabe, K., Mistrík, M., Veselá, E., Protivankova, I., Mailand, N., Lee, M., Masai, H., Lukas, J., & Bartek, J. (2013) · Genes & Development · doi:10.1101/gad.224568.113 · Cited by 81 · see citing works
Multifaceted Recognition of Vertebrate Rev1 by Translesion Polymerases ζ and κ
Wojtaszek, J. L., Liu, J., D’Souza, S., Wang, S., Xue, J. Y., Walker, G. C., & Zhou, P. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.380998 · Cited by 78 · see citing works
Self-citationHaynes, B. M., Saadat, N., Myung, B., & Shekhar, M. P. V. (2014) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2014.11.005 · Cited by 77 · see citing works
Pozhidaeva, A., Pustovalova, Y., D’Souza, S., Bezsonova, I., Walker, G. C., & Korzhnev, D. M. (2012) · Biochemistry · doi:10.1021/bi300566z · Cited by 77 · see citing works
Self-citationMultifunctional platinum‐based nanoparticles for biomedical applications
Cheng, Q., & Liu, Y. (2016) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1410 · Cited by 76 · see citing works
Roles of trans-lesion synthesis (TLS) DNA polymerases in tumorigenesis and cancer therapy
Anand, J. R., Chiou, L. F., Sciandra, C. A., Zhang, X., Hong, J., Wu, D., Zhou, P., & Vaziri, C. (2023) · NAR Cancer · doi:10.1093/narcan/zcad005 · Cited by 73 · see citing works
Involvement of translesion synthesis DNA polymerases in DNA interstrand crosslink repair
Roy, U., & Schärer, O. D. (2016) · DNA repair · doi:10.1016/j.dnarep.2016.05.004 · Cited by 73 · see citing works
Nanoparticle-based drug delivery systems with platinum drugs for overcoming cancer drug resistance
Xie, P., Wang, Y., Wei, D., Zhang, L., Zhang, B., Xiao, H., Song, H., & Mao, X. (2021) · Journal of Materials Chemistry B · doi:10.1039/d1tb00753j · Cited by 70 · see citing works
Peng, C., Chen, Z., Wang, S., Wang, H., Qiu, W., Zhao, L., Xu, R., Luo, H., Chen, D., Chen, D., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1884 · Cited by 69 · see citing works
Sharma, S., Helchowski, C. M., & Canman, C. E. (2012) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2012.11.002 · Cited by 67 · see citing works
Structure and mechanism of B-family DNA polymerase ζ specialized for translesion DNA synthesis
Malik, R., Kopylov, M., Gómez-Llorente, Y., Jain, R., Johnson, R. E., Prakash, L., Prakash, S., Ubarretxena‐Belandia, I., & Aggarwal, A. K. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-0476-7 · Cited by 67 · see citing works
Breaking the DNA damage response to improve cervical cancer treatment
Wieringa, H. W., van der Zee, A. G. J., de Vries, E. G. E., & van Vugt, M. A. T. M. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.11.008 · Cited by 65 · see citing works
DNA Polymerase ζ Is a Major Determinant of Resistance to Platinum-Based Chemotherapeutic Agents
Sharma, S., Shah, N. A., Joiner, A. M., Roberts, K. H., & Canman, C. E. (2012) · Molecular Pharmacology · doi:10.1124/mol.111.076828 · Cited by 64 · see citing works
Ziv, O., Zeisel, A., Mirlas-Neisberg, N., Swain, U., Nevo, R., Ben-Chetrit, N., Martelli, M. P., Rossi, R., Schiesser, S., Canman, C. E., et al. (2014) · Nature Communications · doi:10.1038/ncomms6437 · Cited by 59 · see citing works
Translesion DNA synthesis in the context of cancer research
Knobel, P. A., & Marti, T. M. (2011) · Cancer Cell International · doi:10.1186/1475-2867-11-39 · Cited by 59 · see citing works
Human REV3 DNA Polymerase Zeta Localizes to Mitochondria and Protects the Mitochondrial Genome
Singh, B., Li, X., Owens, K. M., Vanniarajan, A., Liang, P., & Singh, K. K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140409 · Cited by 59 · see citing works
Targeting the Translesion Synthesis Pathway for the Development of Anti-Cancer Chemotherapeutics
Korzhnev, D. M., & Hadden, M. K. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00596 · Cited by 58 · see citing works
Suppression of REV 7 enhances cisplatin sensitivity in ovarian clear cell carcinoma cells
Niimi, K., Murakumo, Y., Watanabe, N., Kato, T., Mii, S., Enomoto, A., Asai, M., Asai, N., Yamamoto, E., Kajiyama, H., et al. (2014) · Cancer Science · doi:10.1111/cas.12390 · Cited by 56 · see citing works
Inhibition of REV3 Expression Induces Persistent DNA Damage and Growth Arrest in Cancer Cells
Knobel, P. A., Kotov, I. N., Felley‐Bosco, E., Stahel, R. A., & Marti, T. M. (2011) · Neoplasia · doi:10.1593/neo.11828 · Cited by 55 · see citing works
Mechanisms of Post-Replication DNA Repair
Gao, Y., Mutter‐Rottmayer, E., Zlatanou, A., Vaziri, C., & Yang, Y. (2017) · Genes · doi:10.3390/genes8020064 · Cited by 55 · see citing works
Chatterjee, N., Whitman, M. A., Harris, C. A., Min, S. M., Jonas, O. H., Lien, E. C., Luengo, A., Heiden, M. G. V., Hong, J., Zhou, P., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2016064117 · Cited by 55 · see citing works
Self-citationREV1 and DNA polymerase zeta in DNA interstrand crosslink repair
Sharma, S., & Canman, C. E. (2012) · Environmental and Molecular Mutagenesis · doi:10.1002/em.21736 · Cited by 54 · see citing works
Han, B., Gao, G., Wu, W., Gao, Z., Zhao, X., Li, L., Qiao, R., Chen, H., Wei, Q., Wu, J., et al. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.09.001 · Cited by 53 · see citing works
Sail, V., Rizzo, A. A., Chatterjee, N., Dash, R. C., Ozen, Z., Walker, G. C., Korzhnev, D. M., & Hadden, M. K. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.6b01144 · Cited by 52 · see citing works
Self-citationA PolH Transcript with a Short 3′UTR Enhances PolH Expression and Mediates Cisplatin Resistance
Zhang, J., Sun, W., Ren, C., Kong, X., Yan, W., & Chen, X. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3928 · Cited by 52 · see citing works
Ancient genes establish stress-induced mutation as a hallmark of cancer
Cisneros, L. H., Bussey, K. J., Orr, A. J., Miočević, M., Lineweaver, C. H., & Davies, P. C. W. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176258 · Cited by 47 · see citing works
Yoon, J.-H., Park, J., Conde, J., Wakamiya, M., Prakash, L., & Prakash, S. (2015) · Genes & Development · doi:10.1101/gad.272229.115 · Cited by 47 · see citing works
REV3L, a Promising Target in Regulating the Chemosensitivity of Cervical Cancer Cells
Yang, L., Shi, T., Liu, F., Ren, C., Wang, Z., Li, Y.-Y., Tu, X., Yang, G. S., & Cheng, X. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120334 · Cited by 46 · see citing works
Targeting the microRNA-regulating DNA damage/repair pathways in cancer
Bottai, G., Pasculli, B., Călin, G. A., & Santarpia, L. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.950650 · Cited by 45 · see citing works
Structural insights into the assembly of human translesion polymerase complexes
Xie, W., Yang, X., Xu, M., & Jiang, T. (2012) · Protein & Cell · doi:10.1007/s13238-012-2102-x · Cited by 44 · see citing works
Translesion synthesis ofO4-alkylthymidine lesions in human cells
Wu, J., Li, L., Wang, P., You, C., Williams, N. L., & Wang, Y. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw662 · Cited by 43 · see citing works
Identification of the first small-molecule inhibitor of the REV7 DNA repair protein interaction
Actis, M. L., Ambaye, N. D., Evison, B. J., Shao, Y., Vanarotti, M., Inoue, A., McDonald, E. T., Kikuchi, S., Heath, R., Hara, K., et al. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.07.026 · Cited by 42 · see citing works
Kochenova, O. V., Daee, D. L., Mertz, T. M., & Shcherbakova, P. V. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005110 · Cited by 42 · see citing works
Overcoming multiple drug resistance in lung cancer using siRNA targeted therapy
Naghizadeh, S., Mohammadi, A., Baradaran, B., & Mansoori, B. (2019) · Gene · doi:10.1016/j.gene.2019.143972 · Cited by 41 · see citing works
Kong, Y. W., Dreaden, E. C., Morandell, S., Zhou, W., Dhara, S. S., Sriram, G., Lam, F. C., Patterson, J. C., Quadir, M., Dinh, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17958-z · Cited by 41 · see citing works
Self-citationTranslesion synthesis inhibitors as a new class of cancer chemotherapeutics
Patel, S. M., Dash, R. C., & Hadden, M. K. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1850692 · Cited by 39 · see citing works
Drug resistance in the mouse cancer clinic
Rottenberg, S., & Borst, P. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.01.001 · Cited by 39 · see citing works
Dual role for mammalian DNA polymerase ζ in maintaining genome stability and proliferative responses
Lange, S. S., Bedford, E., Reh, S., Wittschieben, J. P., Carbajal, S., Kusewitt, D. F., DiGiovanni, J., & Wood, R. D. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217425110 · Cited by 39 · see citing works
The Rev1-Polζ translesion synthesis mutasome: Structure, interactions and inhibition
Rizzo, A. A., & Korzhnev, D. M. (2019) · The Enzymes · doi:10.1016/bs.enz.2019.07.001 · Cited by 39 · see citing works
DNA polymerase eta: A potential pharmacological target for cancer therapy
Saha, P., Mandal, T., Talukdar, A. D., Kumar, D., Kumar, S., Tripathi, P. P., Wang, Q., & Srivastava, A. K. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30155 · Cited by 39 · see citing works
Chun, A. C. S., Kok, K., & Jin, D. (2013) · Cell Cycle · doi:10.4161/cc.23214 · Cited by 38 · see citing works
Multifunctional Role of Astrocyte Elevated Gene-1 (AEG-1) in Cancer: Focus on Drug Resistance
Manna, D., & Sarkar, D. (2021) · Cancers · doi:10.3390/cancers13081792 · Cited by 38 · see citing works
Biomedical,clinical and environmental applications of platinum-based nanohybrids: An updated review
Yerpude, S. T., Potbhare, A. K., Bhilkar, P. R., Rai, A. R., Singh, R. P., Abdala, A. A., Adhikari, R., Sharma, R., & Chaudhary, R. G. (2023) · Environmental Research · doi:10.1016/j.envres.2023.116148 · Cited by 38 · see citing works
Barnes, R. P., Tsao, W.-C., Moldovan, G., & Eckert, K. A. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3931 · Cited by 37 · see citing works
Germline genome protection: implications for gamete quality and germ cell tumorigenesis
Bloom, J. C., Loehr, A. R., Schimenti, J. C., & Weiss, R. S. (2019) · Andrology · doi:10.1111/andr.12651 · Cited by 36 · see citing works
Targeting translesion synthesis (TLS) to expose replication gaps, a unique cancer vulnerability
Nayak, S. U., Calvo, J. A., & Cantor, S. B. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1864321 · Cited by 36 · see citing works
Lesion bypass by S. cerevisiae Pol ζ alone
Stone, J. E., Kumar, D., Binz, S. K., Inase, A., Iwai, S., Chabes, A., Burgers, P., & Kunkel, T. A. (2011) · DNA repair · doi:10.1016/j.dnarep.2011.04.032 · Cited by 36 · see citing works
RAD18 mediates resistance to ionizing radiation in human glioma cells
Xie, C., Wang, H., Cheng, H., Li, J., Wang, Z., & Wu, Y. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.02.003 · Cited by 36 · see citing works
Wu, B., Wang, H., Zhang, L., Sun, C., Li, H., Jiang, C., & Liu, X. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.01.016 · Cited by 35 · see citing works
Chromatin Regulates Genome Targeting with Cisplatin
Zacharioudakis, E., Agarwal, P., Bartoli, A., Abell, N. S., Kunalingam, L., Bergoglio, V., Xhemalçe, B., Miller, K. M., & Rodriguez, R. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201701144 · Cited by 34 · see citing works
Lange, S. S., Tomida, J., Boulware, K. S., Bhetawal, S., & Wood, R. D. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1005759 · Cited by 34 · see citing works
The Regulation of DNA Damage Tolerance by Ubiquitin and Ubiquitin-Like Modifiers
Cipolla, L., Maffia, A., Bertoletti, F., & Sabbioneda, S. (2016) · Frontiers in Genetics · doi:10.3389/fgene.2016.00105 · Cited by 34 · see citing works
Thrall, E. S., Kath, J. E., Chang, S., & Loparo, J. J. (2017) · Nature Communications · doi:10.1038/s41467-017-02333-2 · Cited by 32 · see citing works
Vassel, F.-M., Bian, K., Walker, G. C., & Hemann, M. T. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2016067117 · Cited by 32 · see citing works
Self-citationStanzione, M., Zhong, J., Wong, E., LaSalle, T. J., Wise, J. F., Simoneau, A., Myers, D. T., Phat, S., Sade-Feldman, M., Lawrence, M. S., et al. (2022) · Science Advances · doi:10.1126/sciadv.abn1229 · Cited by 31 · see citing works
Roy, U., Mukherjee, S., Sharma, A., Frank, E. G., & Schärer, O. D. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw485 · Cited by 31 · see citing works
Kim, J. Y., Kim, S.-K., Kang, D., & Moon, M. H. (2012) · Analytical Chemistry · doi:10.1021/ac300772w · Cited by 30 · see citing works
Can pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy?
Roco, Á., Cayún, J. P., Castillo, S. C., Stojanova, J., & Quiñones, L. A. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00391 · Cited by 30 · see citing works
Sakurai, Y., Ichinoe, M., Yoshida, K., Nakazato, Y., Saito, S., Satoh, M., Nakada, N., Sanoyama, I., Umezawa, A., Numata, Y., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.06.001 · Cited by 30 · see citing works
Replication Fork Remodeling and Therapy Escape in DNA Damage Response-Deficient Cancers
Liptay, M., Barbosa, J. S., & Rottenberg, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00670 · Cited by 29 · see citing works
- Authors
- Doles, J., Oliver, T. G., Cameron, E. R., Hsu, G., Jacks, T., Walker, G. C., & Hemann, M. T.
- Affiliations
- Koch Institute for Integrative Cancer Research At MIT (US)
- Howard Hughes Medical Institute (US)
- Department of Biology, and
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2010-11-10
- Volume
- 107
- Issue
- 48
- Pages
- 20786-20791
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2996428
- OpenAlex
- W2012012836
- Cited by
- 190
- References
- 40
- Citations by year
- 2026: 5 · 2025: 3 · 2024: 5 · 2023: 8 · 2022: 6 · 2021: 11 · 2020: 26 · 2019: 14 · 2018: 5 · 2017: 16 · 2016: 17 · 2015: 18 · 2014: 16 · 2013: 13 · 2012: 18
- FWCI
- 5.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
- Funders
- Howard Hughes Medical Institute
- Massachusetts Institute of Technology (P30-CA14051)
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (P30-CA14051, Grant P30-CA14051)
- National Institutes of Health (5r01ca128803-05, ES002109)
- Ludwig Center at Harvard
- National Cancer Institute (R01-CA128803, CA14051, Koch Institute Support (core) Grant P30-CA14051, Grant P30-CA14051, P30CA014051, P30-CA-14051)
- National Institute of Environmental Health Sciences (ES-015818, P30ES002109, R56ES015818, R01ES015818)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- REV3, pol, translesion synthesis, cisplatin resistance, non-small cell lung cancer, lung adenocarcinoma, chemoresistance, secondary malignancies, tumor transplantation, adjuvant therapy, DNA polymerase
- MeSH terms
- Adenocarcinoma, Animals, Cisplatin, DNA-Directed DNA Polymerase, DNA-Binding Proteins, Drug Screening Assays, Antitumor, Lung Neoplasms, Neoplasm Transplantation, Tumor Suppressor Protein p53, Proto-Oncogene Proteins p21(ras), Drug Resistance, Neoplasm, Catalytic Domain, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
